Skip to main content
logo
Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
325.42
+5.17 (1.61%)
Oct 20, 2026, 4:00 PM EDT - Market closed

Krystal Biotech Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
440.48389.13290.5250.7--
Revenue Growth
22.63%33.95%473.02%---
Gross Profit
416.87366.08270.4547.61--
Operating Income
197.75161.3103.25-97.12-121.3-69.88
Net Income
241.46204.8389.1610.93-139.98-69.57
Earnings Per Share
7.976.843.000.39-5.49-3.13
EPS Growth
62.40%128.00%669.23%---

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,103955.86749.63594.13383.79502.47
Total Debt
8.859.347.268.098.938.02
Net Cash (Debt)
1,094946.52742.37586.04374.86494.44
Net Cash Growth
34.88%27.50%26.68%56.34%-24.19%84.97%
Net Cash Per Share
36.0731.6024.9621.1214.7022.28

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
272.34200.87123.42-88.8-100.57-47.94
Capital Expenditures
-14.56-11.95-4.24-11.8-52.98-68.34
Free Cash Flow
257.78188.91119.18-100.6-153.55-116.27
Free Cash Flow Growth
39.01%58.51%----

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
94.64%94.08%93.09%93.90%--
Operating Margin
44.89%41.45%35.54%-191.56%--
Pretax Margin
51.45%48.69%32.82%25.44%--
Profit Margin
54.82%52.64%30.69%21.56%--
FCF Margin
58.52%48.55%41.02%-198.43%--

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
40.8534.9050.54320.10--
Forward PE
40.4634.8933.31---
P/FCF Ratio
37.3737.8437.81---
PS Ratio
21.8718.3715.5169.02--